Identification of a novel allosteric binding site in the CXCR2 chemokine receptor

Molecular Pharmacology

Volumn 80, Issue 6, 2011, Pages 1108-1118

  De Kruijf, Petra ^a   Lim, Herman D ^a   Roumen, Luc ^a   Renjaän, Véronique A ^a   Zhao, Jiuqiao ^c,d   Webb, Maria L ^c,e   Auld, Douglas S ^c,f   Wijkmans, Jac C H M ^b   Zaman, Guido J R ^b   Smit, Martine J ^a   De Graaf, Chris ^a   Leurs, Rob ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PHARMACOPEIA INC   (United States)

^d JBristol Myers Squibb Company   (United States)

^e Venenum   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (1H IMIDAZOL 1 YL) 6 (OCTYLTHIO)PYRIMIDIN 4 YLAMINO] N (3 ETHOXYPROPYL) 4 METHYLPENTANAMIDE; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; N (2 BROMOPHENYL) N' (7 CYANO 1H BENZOTRIAZOL 4 YL)UREA; OPSIN; PYRIMIDINE DERIVATIVE; SB 265610; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; LIGAND BINDING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; RHESUS MONKEY; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

ALLOSTERIC SITE; AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; GORILLA GORILLA; HUMANS; LIGANDS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PAN TROGLODYTES; PAPIO; PONGO PYGMAEUS; RECEPTORS, INTERLEUKIN-8B; ROD OPSINS; SPECIES SPECIFICITY;

EID: 81555222803     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.073825     Document Type: Article

References (40)

1. Ajuebor MN, Zagorski J, Kunkel SL, Strieter RM, and Hogaboam CM (2004) Contrasting roles for CXCR2 during experimental colitis. Exp Mol Pathol 76:1-8. (Pubitemid 38096312)
2. Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, et al. (2005) 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem 48:4312-4331. (Pubitemid 40884935)
3. Andrews G, Jones C, and Wreggett KA (2008) An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol 73:855-867. (Pubitemid 351397890)
4. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
5. Baxter A, Cooper A, Kinchin E, Moakes K, Unitt J, and Wallace A (2006) Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett 16:960-963. (Pubitemid 43059860)
6. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, et al. (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101:11791-11796. (Pubitemid 39095373)
7. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, and Allegretti M (2006) ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 112:139-149. (Pubitemid 44314001)
8. Boisvert WA, Santiago R, Curtiss LK, and Terkeltaub RA (1998) A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 101:353-363. (Pubitemid 28067332)
9. Buanne P, Di Carlo E, Caputi L, Brandolini L, Mosca M, Cattani F, Pellegrini L, Biordi L, Coletti G, Sorrentino C, et al. (2007) Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol 82:1239-1246. (Pubitemid 350133522)
10. Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, HipKin RW, Fan X, Rindgen D, Deno G, Bond R, et al. (2007) A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 322:486-493. (Pubitemid 47105794)
11. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
12. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265. (Pubitemid 350172884)
13. de Kruijf P, van Heteren J, Lim HD, Conti PG, van der Lee MM, Bosch L, Ho KK, Auld D, Ohlmeyer M, Smit MJ, et al. (2009) Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. J Pharmacol Exp Ther 329:783-790.
14. Deupi X, Olivella M, Sanz A, Dölker N, Campillo M, and Pardo L (2010) Influence of the g- conformation of Ser and Thr on the structure of transmembrane helices. J Struct Biol 169:116-123.
15. Erickson S, Baldwin J, Dolle RE, Inglese J, Ohlmeyer M, Ho KK, Bohnstedt AC, Kultgen SG, Webb ML, Auld DS, et al., inventors; Pharmacopeia, Inc.; Erickson S, Baldwin J, Dolle RE, Inglese J, Ohlmeyer M, Ho KK, Bohnstedt AC, Kultgen SG, Webb ML, assignees. (2004) Pyrimidine derivatives as IL-8 receptor antagonists. World patent WO/2004/062609. 2004 July 29.
16. Govaerts C, Blanpain C, Deupi X, Ballet S, Ballesteros JA, Wodak SJ, Vassart G, Pardo L, and Parmentier M (2001) The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem 276:13217-13225.
17. in RW, Deno G, Fine J, Sun Y, Wilburn B, Fan X, Gonsiorek W, and Wiekowski MT (2004) Cloning and pharmacological characterization of CXCR1 and CXCR2 from Macaca fascicularis. J Pharmacol Exp Ther 310:291-300.
18. Ho KK, Auld DS, Bohnstedt AC, Conti P, Dokter W, Erickson S, Feng D, Inglese J, Kingsbury C, Kultgen SG, et al. (2006) Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg Med Chem Lett 16:2724-2728.
19. Horlick R, Zhao J, Swanson R, Webb M, Strohl B, Baldwin JJ, Auld DS, and Chen XG (2006), inventors; Pharmacopeia Drug Discovery, Inc., assignee. Orthologues of human receptors and methods of use. U.S. patent 7,041,463. 2006 May 9.
20. Hurst DP, Grossfield A, Lynch DL, Feller S, Romo TD, Gawrisch K, Pitman MC, and Reggio PH (2010) A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 285:17954-17964.
21. Kraneveld AD, Braber S, Overbeek S, de Kruijf P, Koelink P and Smit MJ (2011) Chemokine receptors in inflammatory diseases, in Chemokine Receptors as Drug Targets (Smit MJ, Lira SA, Leurs R eds) pp 105-150, Wiley-VCH Verlag GmbH&Co, Weinheim, Germany.
22. Kulke R, Bornscheuer E, Schlüter C, Bartels J, Röwert J, Sticherling M, and Christophers E (1998) The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 110:90-94. (Pubitemid 28086071)
23. Li JJ, Carson KG, Trivedi BK, Yue WS, Ye Q, Glynn RA, Miller SR, Connor DT, Roth BD, Luly JR, et al. (2003) Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin- 8 receptor. Bioorg Med Chem 11:3777-3790. (Pubitemid 36952276)
24. Lim HD, de Graaf C, Jiang W, Sadek P, McGovern PM, Istyastono EP, Bakker RA, de Esch IJ, Thurmond RL, and Leurs R (2010) Molecular determinants of ligand binding to H4R species variants. Mol Pharmacol 77:734-743.
25. Liu L, Darnall L, Hu T, Choi K, Lane TE, and Ransohoff RM (2010) Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells. J Neurosci 30:9074-9083.
26. Milligan G (2011) Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends Pharmacol Sci 32:317-325.
27. Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S, Beccari AR, Bizzarri C, Cavicchia MR, Locati M, et al. (2007) Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem 50:3984-4002. (Pubitemid 47301732)
28. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, and Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:145-176. (Pubitemid 30127598)
29. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, et al. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74:1193-1202.
30. Park JH, Scheerer P, Hofmann KP, Choe HW, and Ernst OP (2008) Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454:183-187. (Pubitemid 351969893)
31. Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, Jin Q, White JR, Lee JM, Goodman RB, et al. (2002) A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 169:6435-6444. (Pubitemid 36903493)
32. Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, and Jeffery PK (2003) Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168:968-975. (Pubitemid 37267175)
33. Reinhart GJ, Xie Q, Liu XJ, Zhu YF, Fan J, Chen C, and Struthers RS (2004) Species selectivity of nonpeptide antagonists of the gonadotropin- releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus. J Biol Chem 279:34115-34122. (Pubitemid 39318033)
34. Rosenkilde MM, Gerlach LO, Jakobsen JS, Skerlj RT, Bridger GJ, and Schwartz TW (2004) Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 279:3033-3041. (Pubitemid 38114296)
35. Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, and Bradley ME (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. British journal of pharmacology 159:1429-1439.
36. Scholten DJ, Canals M, Maussang DM, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer H and Leurs R (2011) Pharmacological modulation of chemokine receptor function. Br J Pharmacol doi:10.1111/j.1476-5381.2011.01551.x.
37. UniProt Consortium (2011) Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res 39:D214-D219.
38. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, and Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623. (Pubitemid 37034158)
39. Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, et al. (2004) Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem 47:1319-1321. (Pubitemid 38327458)
40. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066-1071.